Acute kidney injury treatment market

Acute Kidney Injury Treatment Market, by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, and Postrenal Acute Kidney Injury), by Treatment (Therapy, and Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Oct 2021
CMI4691
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Acute kidney injury occurs when the kidneys suddenly stop filtering waste products from the blood. Kidney failure affects body fluids, electrolytes, and acid-base balance. Acute kidney injury involves prerenal, postrenal, and intrinsic failures. Depending upon the severity of the injury, the treatment involves hemodialysis and continuous renal replacement therapy. Though treatment is not meant to completely cure the kidney, but to improve the kidney function.

The global acute kidney injury treatment market is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028).

Figure 1.Global Acute Kidney Injury Treatment Market Share (%) in Terms of Value, By Type, 2021

Increasing incidence of acute kidney injuries is expected to drive the market growth during the forecast period.

The increasing incidence of acute kidney injuries is expected to drive the global acute kidney injury treatment market growth over the forecast period. For instance, according to International Society of Nephrology, there are around 13.3 million cases of acute kidney injury worldwide each year. Additionally, 1.7 million deaths are caused by acute kidney injury per year globally.

Figure 2.Global Acute Kidney Injury Treatment Market Share (%), By Treatment, 2021

Increasing technological advancements are expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on development of treatments for acute kidney injury, which is expected to drive the global acute kidney injury treatment market growth during the forecast period. For instance, in December 2020, Medtronic plc, a global leader in medical technology, services, and solutions, announced the U.S. commercial launch of the Carpediem cardio-renal pediatric dialysis emergency machine. The first of its kind Carpediem system is indicated for use in acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy. It is intended to provide continuous renal replacement therapy (CRRT) to patients weighing between 2.5 and 10 kilograms.

Acute Kidney Injury Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,857.8 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	7.2%	2028 Value Projection:	US$ 3,031.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, Postrenal Acute Kidney Injury By Treatment: Therapy, Drugs By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp
Growth Drivers:	Increasing incidence of acute kidney injuries Increasing technological advancements Increasing government initiatives
Restraints & Challenges:	High costs for acute kidney injury treatment Lack of awareness among the people regarding the acute kidney injury treatment

Global Acute Kidney Injury Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 235 million infected individuals worldwide as of October 7, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global acute kidney injury treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Acute Kidney Injury Treatment Market: Restraint

The major factors that hinder the growth of the global acute kidney injury treatment market include high costs for acute kidney injury treatment and lack of awareness among the people regarding the acute kidney injury treatment. For instance, according to an article published in Karger Journals in 2017, stated that in the U.S. acute kidney injury is associated with an increase in hospitalization costs that range from US$ 5.4 to US$ 24.0 billion. The patients with high treatment cost are those with acute kidney injury of sufficient severity to require dialysis, where cost increases relative to patients without acute kidney injury range from US$ 11,016 to US$ 42,077 per hospitalization.

Key Players

Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp

Table of Content

*Browse 27 market data tables and 31 figures on "Acute Kidney Injury Treatment Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global acute kidney injury treatment market size is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% between 2021 and 2028.

What are the major factors driving the market growth?

Factors such as increasing incidence of acute kidney injuries, increasing technological advancements, and increasing government initiatives are expected to drive the market growth during the forecast period.

Which is the leading treatment segment in the market?

Drug segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors hampering growth of the global acute kidney injury treatment market include high costs for acute kidney injury treatment and lack of awareness among the people regarding the acute kidney injury treatment.

Which are the major players operating in the market?

Major players operating in the market include Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp